Cargando…

Colonization Screening Targeting Multidrug-Resistant Gram-Negative Pathogens Does Not Increase the Use of Carbapenems in Very Low Birth Weight Infants

Since 2012, a colonization screening (CoS) for multidrug-resistant Gram-negative bacteria (MRGN) in very low birth weight infants (VLWBI) was implemented in order to provide a basis for an effective empiric therapy of subsequent nosocomial infections (NI). According to antibiotic stewardship, carbap...

Descripción completa

Detalles Bibliográficos
Autores principales: Schöndorf, Dominik, Simon, Arne, Wagenpfeil, Gudrun, Gärtner, Barbara, Geipel, Martina, Zemlin, Michael, Schöndorf, Marika, Meyer, Sascha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423965/
https://www.ncbi.nlm.nih.gov/pubmed/32850541
http://dx.doi.org/10.3389/fped.2020.00427
_version_ 1783570235987591168
author Schöndorf, Dominik
Simon, Arne
Wagenpfeil, Gudrun
Gärtner, Barbara
Geipel, Martina
Zemlin, Michael
Schöndorf, Marika
Meyer, Sascha
author_facet Schöndorf, Dominik
Simon, Arne
Wagenpfeil, Gudrun
Gärtner, Barbara
Geipel, Martina
Zemlin, Michael
Schöndorf, Marika
Meyer, Sascha
author_sort Schöndorf, Dominik
collection PubMed
description Since 2012, a colonization screening (CoS) for multidrug-resistant Gram-negative bacteria (MRGN) in very low birth weight infants (VLWBI) was implemented in order to provide a basis for an effective empiric therapy of subsequent nosocomial infections (NI). According to antibiotic stewardship, carbapenems should be reserved for NI caused by MRGN or severe NI. We examined whether the CoS increased the first-line use of carbapenems. In this retrospective cohort analysis, we enrolled all VLBWI before (2009–2011) and after (2012–2014) the introduction of CoS (2012) at a tertiary university neonatal intensive care and neonatal intermediate care unit (NIMC) in Germany. Rectal swabs were used to detect MRGN colonization (on admission and weekly until discharge from the NIMC). The use of carbapenems was measured by days of therapy (DoT). To exclude the replacement of carbapenems by other antibiotics, antibiotic therapy for late-onset sepsis (LOS) was assessed by DoT and length of therapy (LoT). In 55/201 (27.4%) VLBWI, CoS detected MRGN colonization. Compared to the cohort prior to the introduction of CoS (n = 191), a significant decrease in LoT (p < 0.001) and total DoT (p < 0.001) was seen (n = 201). This was due to a significant decrease in LoT (p < 0.001) and total DoT (p < 0.001) in the birth weight category of 1,000–1,499 g. In these infants, DoT for carbapenems (p = 0.009) was significantly lower, possibly caused by a significant decline of LOS (25 episodes vs. 39 episodes, p = 0.025). Conversely, no significant differences in LoT and total DoT were seen in infants with a birth weight <500 g (p = 1.000; p = 0.758) and in infants weighing 500–999 g (p = 0.754; p = 0.794). DoT for carbapenems was not significantly different in the total cohort after the introduction of CoS (p = 0.341). Prolonged exposure to carbapenems (in terms of DoT) significantly postponed the first detection of MRGN colonization (p = 0.023). The introduction of CoS did not result in an increased use of carbapenems. Concomitant carbapenem treatment may reduce the sensitivity of CoS relying on rectal swabs.
format Online
Article
Text
id pubmed-7423965
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74239652020-08-25 Colonization Screening Targeting Multidrug-Resistant Gram-Negative Pathogens Does Not Increase the Use of Carbapenems in Very Low Birth Weight Infants Schöndorf, Dominik Simon, Arne Wagenpfeil, Gudrun Gärtner, Barbara Geipel, Martina Zemlin, Michael Schöndorf, Marika Meyer, Sascha Front Pediatr Pediatrics Since 2012, a colonization screening (CoS) for multidrug-resistant Gram-negative bacteria (MRGN) in very low birth weight infants (VLWBI) was implemented in order to provide a basis for an effective empiric therapy of subsequent nosocomial infections (NI). According to antibiotic stewardship, carbapenems should be reserved for NI caused by MRGN or severe NI. We examined whether the CoS increased the first-line use of carbapenems. In this retrospective cohort analysis, we enrolled all VLBWI before (2009–2011) and after (2012–2014) the introduction of CoS (2012) at a tertiary university neonatal intensive care and neonatal intermediate care unit (NIMC) in Germany. Rectal swabs were used to detect MRGN colonization (on admission and weekly until discharge from the NIMC). The use of carbapenems was measured by days of therapy (DoT). To exclude the replacement of carbapenems by other antibiotics, antibiotic therapy for late-onset sepsis (LOS) was assessed by DoT and length of therapy (LoT). In 55/201 (27.4%) VLBWI, CoS detected MRGN colonization. Compared to the cohort prior to the introduction of CoS (n = 191), a significant decrease in LoT (p < 0.001) and total DoT (p < 0.001) was seen (n = 201). This was due to a significant decrease in LoT (p < 0.001) and total DoT (p < 0.001) in the birth weight category of 1,000–1,499 g. In these infants, DoT for carbapenems (p = 0.009) was significantly lower, possibly caused by a significant decline of LOS (25 episodes vs. 39 episodes, p = 0.025). Conversely, no significant differences in LoT and total DoT were seen in infants with a birth weight <500 g (p = 1.000; p = 0.758) and in infants weighing 500–999 g (p = 0.754; p = 0.794). DoT for carbapenems was not significantly different in the total cohort after the introduction of CoS (p = 0.341). Prolonged exposure to carbapenems (in terms of DoT) significantly postponed the first detection of MRGN colonization (p = 0.023). The introduction of CoS did not result in an increased use of carbapenems. Concomitant carbapenem treatment may reduce the sensitivity of CoS relying on rectal swabs. Frontiers Media S.A. 2020-08-06 /pmc/articles/PMC7423965/ /pubmed/32850541 http://dx.doi.org/10.3389/fped.2020.00427 Text en Copyright © 2020 Schöndorf, Simon, Wagenpfeil, Gärtner, Geipel, Zemlin, Schöndorf and Meyer. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Schöndorf, Dominik
Simon, Arne
Wagenpfeil, Gudrun
Gärtner, Barbara
Geipel, Martina
Zemlin, Michael
Schöndorf, Marika
Meyer, Sascha
Colonization Screening Targeting Multidrug-Resistant Gram-Negative Pathogens Does Not Increase the Use of Carbapenems in Very Low Birth Weight Infants
title Colonization Screening Targeting Multidrug-Resistant Gram-Negative Pathogens Does Not Increase the Use of Carbapenems in Very Low Birth Weight Infants
title_full Colonization Screening Targeting Multidrug-Resistant Gram-Negative Pathogens Does Not Increase the Use of Carbapenems in Very Low Birth Weight Infants
title_fullStr Colonization Screening Targeting Multidrug-Resistant Gram-Negative Pathogens Does Not Increase the Use of Carbapenems in Very Low Birth Weight Infants
title_full_unstemmed Colonization Screening Targeting Multidrug-Resistant Gram-Negative Pathogens Does Not Increase the Use of Carbapenems in Very Low Birth Weight Infants
title_short Colonization Screening Targeting Multidrug-Resistant Gram-Negative Pathogens Does Not Increase the Use of Carbapenems in Very Low Birth Weight Infants
title_sort colonization screening targeting multidrug-resistant gram-negative pathogens does not increase the use of carbapenems in very low birth weight infants
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423965/
https://www.ncbi.nlm.nih.gov/pubmed/32850541
http://dx.doi.org/10.3389/fped.2020.00427
work_keys_str_mv AT schondorfdominik colonizationscreeningtargetingmultidrugresistantgramnegativepathogensdoesnotincreasetheuseofcarbapenemsinverylowbirthweightinfants
AT simonarne colonizationscreeningtargetingmultidrugresistantgramnegativepathogensdoesnotincreasetheuseofcarbapenemsinverylowbirthweightinfants
AT wagenpfeilgudrun colonizationscreeningtargetingmultidrugresistantgramnegativepathogensdoesnotincreasetheuseofcarbapenemsinverylowbirthweightinfants
AT gartnerbarbara colonizationscreeningtargetingmultidrugresistantgramnegativepathogensdoesnotincreasetheuseofcarbapenemsinverylowbirthweightinfants
AT geipelmartina colonizationscreeningtargetingmultidrugresistantgramnegativepathogensdoesnotincreasetheuseofcarbapenemsinverylowbirthweightinfants
AT zemlinmichael colonizationscreeningtargetingmultidrugresistantgramnegativepathogensdoesnotincreasetheuseofcarbapenemsinverylowbirthweightinfants
AT schondorfmarika colonizationscreeningtargetingmultidrugresistantgramnegativepathogensdoesnotincreasetheuseofcarbapenemsinverylowbirthweightinfants
AT meyersascha colonizationscreeningtargetingmultidrugresistantgramnegativepathogensdoesnotincreasetheuseofcarbapenemsinverylowbirthweightinfants